… financial results for the second quarter ended April 30, 2025 … joined enGene from Astellas Pharma, where she most recently … with this distinction. Second Quarter 2025 Financial Results As … debt obligations and capital expenditures into 2027. Three Months …

…     —%     7%                                         Second Quarter CooperSurgical (CSI) Revenue Revenue of …                                 Other During the second quarter of fiscal 2025, the company … capital expenditures. We … or pharmaceutical industries …

… financial results for the second quarter ended March 31, 2025 … Significant Corporate Accomplishments in Q2 2025 and Subsequently: … for the food, pharmaceutical and cannabis industries that … , market position, expected expenditures, and the expected synergies …

… financial results for the second quarter ended March 31, 2025 … discuss the results for Q2 2025 and business … solution for the food, pharmaceutical and cannabis industries that … development, market position, expected expenditures, and the expected synergies …

… financial results for the second quarter ended March 31, 2025 … discuss the results for Q2 2025 and business … solution for the food, pharmaceutical and cannabis industries that … development, market position, expected expenditures, and the expected synergies …

… Inc. (NYSE:A) Q2 2025 Earnings Call Transcript … press release for our second quarter financial results, investor presentation … $114 million in capital expenditures. We purchased $165 … leadership experience from the pharmaceutical, biotechnology and healthcare …

… several purchase orders from pharmaceutical companies to co-package … in accordance with GAAP. Second Quarter Fiscal Year 2025 Results: … May 28, 2025. Second Quarter Fiscal Year 2025 Earnings … 2   Investing Activities       Capital expenditures $ (1.6 )   $ ( …

… by our pharmaceutical distribution footprint … second quarter primarily due to share repurchases. Second Quarter … second quarter. Segment operating income in the second quarter …         Investing Activities:       Capital expenditures   (234,953 )     (186,970 ) …

… Optimization in the second quarter and lower pharma carry-over pricing … 3 million during the second quarter. The lower Adjusted … 2 million during the second quarter. Excluding this, Adjusted … mandatory versus discretionary expenditures can vary significantly …

… during this period.” Second Quarter Fiscal 2025 Consolidated Results … except per share data) Q2 FY2025   Q2 FY2024   Change     … lines for the packaging, pharma, foil, décor and … flows from investing activities:       Capital expenditures   (18,271 )     (24 …